Emmanuelle L. R.
- Country
- France
- Department
- Service d’Hématologie
Research Overview
- Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Patients with Relapsed/Refractory Multiple Myeloma Following BCMA-Targeting CAR-T or Bispecific Antibody Therapy
- Phase 3 Randomized Study of Iberdomide, Daratumumab, and Dexamethasone vs. Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 4 of 98 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating relapsed and refractory multiple myeloma, a complex blood cancer condition that requires innovative therapeutic approaches.
- Multiple Myeloma Management
- Blood Cancer Therapeutics
- Hematologic Malignancies
Their research interests encompass novel therapeutic combinations for treating resistant forms of multiple myeloma.
Novel Therapeutic Combinations
The investigator focuses on evaluating innovative treatment combinations involving targeted therapies and immunomodulatory drugs for blood cancer treatment.
- Combination Therapy Approaches
- Immunotherapy Integration
- Treatment Resistance
Their work explores the effectiveness of combining different therapeutic agents to improve patient outcomes.
Treatment Response Assessment
The investigator specializes in evaluating minimal residual disease and disease progression markers in multiple myeloma patients.
- Disease Response Monitoring
- Progressive Disease Management
- Clinical Outcomes Assessment
Their expertise includes measuring treatment efficacy through sophisticated disease monitoring techniques.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.